Tandem Diabetes Care (LTS:0M0F) Accounts Payable: $60 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0M0F Tandem Diabetes Care Inc LTS:0M0F
68 GF Score
Price $16.75
GF Value $29.82
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is Tandem Diabetes Care Accounts Payable?

Tandem Diabetes Care LTS:0M0F +2.47% 68 Accounts Payable is $60 Mil as of Mar. 2026. GuruFocus rates LTS:0M0F with a GF Score™ of 68/100 and a GF Value™ of $29.82 (Possible Value Trap). The stock has 5 warning signs investors should review.

Tandem Diabetes Care's Accounts Payable for the quarter that ended in Mar. 2026 was $60 Mil.

Tandem Diabetes Care's quarterly Accounts Payable declined from Sep. 2025 ($47 Mil) to Dec. 2025 ($47 Mil) but then increased from Dec. 2025 ($47 Mil) to Mar. 2026 ($60 Mil).

Tandem Diabetes Care's annual Accounts Payable declined from Dec. 2023 ($50 Mil) to Dec. 2024 ($45 Mil) but then increased from Dec. 2024 ($45 Mil) to Dec. 2025 ($47 Mil).

Tandem Diabetes Care Accounts Payable Related Terms

Tandem Diabetes Care Accounts Payable Historical Data

* Premium members only.

The historical data trend for Tandem Diabetes Care's Accounts Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Tandem Diabetes Care Accounts Payable Chart

Tandem Diabetes Care Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Accounts Payable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 28.03 55.73 49.59 44.73 47.07

Tandem Diabetes Care Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Accounts Payable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 59.80 55.84 47.48 47.07 59.86
LTS:0M0F
68GF Score
Tandem Diabetes Care Inc LTS:0M0F
Accounts Payable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Tandem Diabetes Care Accounts Payable Calculation

Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.

Frequently Asked Questions Learn more about Accounts Payable →
What does a Accounts Payable of $60 Mil mean?
Tandem Diabetes Care (LTS:0M0F) has a Accounts Payable of $60 Mil as of Mar. 2026. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Tandem Diabetes Care and its competitors.
Is Tandem Diabetes Care's Accounts Payable too high?
Tandem Diabetes Care's current Accounts Payable is $60 Mil. Overall, Tandem Diabetes Care has a GF Score™ of 68/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Tandem Diabetes Care's Accounts Payable compare to CNMD and AORT?
Tandem Diabetes Care's Accounts Payable of $60 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accounts Payable for a Medical Devices & Instruments company?
A good Accounts Payable depends on the Medical Devices & Instruments industry context. However, Accounts Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accounts Payable mean?
A high Accounts Payable can signal that a stock is expensive relative to its fundamentals. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Tandem Diabetes Care and its competitors. Tandem Diabetes Care's current Accounts Payable is $60 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tandem Diabetes Care stock overvalued right now?
Based on GuruFocus' analysis, Tandem Diabetes Care (LTS:0M0F) is currently considered Possible Value Trap. The stock's GF Value™ is $29.82, compared to a current price of $16.75 — trading 43.8% below its estimated fair value. The current Accounts Payable is $60 Mil. Tandem Diabetes Care's overall GF Score™ is 68/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accounts Payable calculated?
Accounts Payable is calculated from a company's financial statements. For Tandem Diabetes Care (LTS:0M0F), the current Accounts Payable is $60 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Tandem Diabetes Care (LTS:0M0F) Overvalued in 2026?

Based on GuruFocus' analysis, Tandem Diabetes Care stock appears to be undervalued. The current stock price of $16.75 is trading 43.8% below its estimated GF Value™ of $29.82. GuruFocus considers Tandem Diabetes Care to be Possible Value Trap.

Key valuation signals for LTS:0M0F:

  • Accounts Payable: $60 Mil
  • GF Value™: $29.82 vs. price of $16.75 (43.8% below fair value)
  • GF Score™: 68/100 with 5 warning signs

No single metric tells the full story. See the LTS:0M0F stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Tandem Diabetes Care Business Description

Address 12400 High Bluff Drive, San Diego, CA, USA, 92130
Tandem Diabetes designs, manufactures, and markets durable insulin pumps for individuals with diabetes. The firm first entered this market in 2012 and has since introduced multiple generations of pumps leading to its current t:slim X2 device. The firm recently launched its smaller Mobi pump and continues to work on Tobi (a tubeless version of Mobi), and the Sigi tubeless patch pump. Nearly three-quarters of total revenue is derived from the US, with the remainder primarily from other developed nations. The pumps themselves generate just over half of total sales, and another one-third is from disposable infusion sets that need to be changed over every 2 to 3 days.
68GF Score

Get the complete analysis for LTS:0M0F

Accounts Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$16.75
Price
$29.82
GF Value